Skip to main content

Menopausal Hormone Therapy and Non-Hormonal Options Shortages in Australia – Update 23 June 2021

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Duavive – supply due to be resolved by end January 2022

Progynova 2mg – supply due to be resolved by end of April 2022

Femonston Conti – supply shortage expected between 25 June and 9 July

 

Transdermal MHT

Estradot 100 – supply due to be resolved by 31 August

Estradot 75 – supply due to be resolved by 31 August

Estradot 50 – supply due to be resolved by 1 July

Estradot 37.5 – supply due to be resolved by 31 August

Estradot 25 – supply due to be resolved by 1 July

Estalis Conti 50/140 – supply resolved

Estalis Conti 50/250 – supply resolved

Estalis Sequi 50/140 – supply resolved

Estalis Sequi 50/250 – supply resolved

Estraderm MX 50 – supply resolved

Estraderm MX 100 - supply resolved

Non-Hormonal Options

There is also an expected shortage of supply of non-hormonal treatment options:

Gabapentin-APOTEX 100mg – supply shortage expected between 20 August- 15 October

Gabapentin 300mg- supply shortage expected between 18 June- 16 July

APX-Gabapentin 300mg- supply shortage expected between 16 July- 6 August

Gabapentin-APOTEX 300mg – to be discontinued from 18 July

Combined oral contraceptive pill

There is also an expected shortage of combined oral contraceptive pill:

Qliara – supply due to be resolved by 1 June 2022

Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.

Read more …Menopausal Hormone Therapy and Non-Hormonal Options Shortages in Australia – Update 23 June 2021

Menopausal Hormone Therapy Shortages in Australia – Update 22 February 2021

There has been a recent shortage of a number of menopausal hormone therapy (MHT) preparations and some of these have now been or soon will be resolved:

Oral MHT

Duavive – supply due to be resolved by end January 2022 

Transdermal

Estradot 100 – supply due to be resolved by the end of March

Estradot 75 – supply due to be resolved by the end of April

Estradot 50 – supply due to be resolved by the end of March

Estradot 37.5 – supply due to be resolved by the end of March

Estradot 25 – supply due to be resolved by the end of April

Estalis Conti 50/140 - supply due to be resolved by early April

Estalis Conti 50/250 - supply due to be resolved by early April

Estalis Sequi 50/140 – supply due to be resolved by early May

Estalis Sequi 50/250 – supply due to be resolved by early May

Estraderm MX 50 – supply due to be resolved by end of April

Estraderm MX 100 - supply due to be resolved by end of April

Please note that dates for supply have been sourced from either the pharmaceutical supplier or the TGA website and may change at any time.

Read more …Menopausal Hormone Therapy Shortages in Australia – Update 22 February 2021